1
|
Faye MD, Petruccelli Araujo M, Wissing MD, Alrabiah K, Gilbert L, Zeng X, Souhami L, Alfieri J. Safety and Efficacy of 2D Brachytherapy vs. 3D Image-Guided Adaptive Brachytherapy for Locally Advanced Cervical Cancer-A Single Institution Retrospective Study. Curr Oncol 2023; 30:4966-4978. [PMID: 37232833 DOI: 10.3390/curroncol30050375] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/23/2023] [Revised: 05/03/2023] [Accepted: 05/09/2023] [Indexed: 05/27/2023] Open
Abstract
BACKGROUND The treatment paradigm for locally advanced cervical cancer (LACC) has shifted from two-dimensional-brachytherapy (2D-BT) to three-dimensional-image-guided adaptive BT (3D-IGABT). In this retrospective study, we report our experience with the change from 2D-BT to 3D-IGABT. METHODS We reviewed 146 LACC patients (98 3D-IGABT and 48 2D-BT) who received chemoradiation between 2004 and 2019. The multivariable odds ratio (OR) for treatment-related toxicities and hazard ratios (HR) for locoregional control (LRC), distant control (DC), failure-free survival (FFS), cancer-specific survival (CSS) and overall survival (OS) are reported. RESULTS The median follow-up was 50.3 months. There was a significant decrease in overall late toxicities in the 3D-IGABT group compared to the 2D-BT group (OR 0.22[0.10-0.52]), late gastrointestinal (OR 0.31[0.10-0.93]), genitourinary (OR 0.31[0.09-1.01]) and vaginal toxicities (0% vs. 29.6%). Grade ≥ 3 toxicity was low in both groups (2D-BT: 8.2% acute, 13.3% late vs. 3D-IGABT: 6.3% acute, 4.4% late, NS). The five-year LRC, DC, FFS, CSS and OS for 3D-IGABT were 92.0%, 63.4%, 61.7%, 75.4% and 73.6%, compared to 87.3%, 71.8%, 63.7%, 76.3% and 70.8% for 2D-BT (NS). CONCLUSIONS 3D-IGABT for the treatment of LACC is associated with a decrease in overall late gastrointestinal, genitourinary and vaginal toxicities. The disease control or survival outcomes were comparable to contemporary 3D-IGABT studies.
Collapse
Affiliation(s)
- Mame Daro Faye
- Division of Radiation Oncology, McGill University Health Centre, Montreal, QC H4A 3J1, Canada
| | | | - Michel D Wissing
- Division of Cancer Epidemiology, Oncology, McGill University, Montreal, QC H4A 3T2, Canada
| | - Khalid Alrabiah
- Division of Radiation Oncology, McGill University Health Centre, Montreal, QC H4A 3J1, Canada
| | - Lucy Gilbert
- Department of Gynecology-Oncology, McGill University Health Centre, Montreal, QC H4A 3J1, Canada
| | - Xing Zeng
- Department of Gynecology-Oncology, McGill University Health Centre, Montreal, QC H4A 3J1, Canada
| | - Luis Souhami
- Division of Radiation Oncology, McGill University Health Centre, Montreal, QC H4A 3J1, Canada
| | - Joanne Alfieri
- Division of Radiation Oncology, McGill University Health Centre, Montreal, QC H4A 3J1, Canada
| |
Collapse
|
2
|
Faye MD, Easaw J, De Robles P, Agnihotram R, Torres-Vasquez A, Lamonde F, Petrecca K, Owen S, Panet-Raymond V, Shenouda G, Souhami L, Azam M, Hossain B, Alkass J, Sabri S, Abdulkarim B. Phase II trial of concurrent sunitinib, temozolomide, and radiotherapy with adjuvant temozolomide for newly diagnosed MGMT unmethylated glioblastoma. Neurooncol Adv 2023; 5:vdad106. [PMID: 37771465 PMCID: PMC10530294 DOI: 10.1093/noajnl/vdad106] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 09/30/2023] Open
Abstract
Background The overall prognosis of glioblastoma (GBM) remains dismal, particularly for patients with unmethylated O6-methylguanine-DNA-methyltransferase (MGMT) promoter. In this phase II trial, we tested the combination of the antiangiogenic agent sunitinib with radiotherapy and temozolomide (TMZ) for newly diagnosed unmethylated MGMT GBM patients. Methods We enrolled 37 patients with unmethylated MGMT promoter GBM, age 18-70, and KPS ≥70. Patients received 12.5 mg of daily sunitinib for 7 days, followed by concurrent chemoradiation plus 12.5 mg sunitinib, then adjuvant TMZ. The primary endpoint was progression-free survival (PFS), and secondary endpoints were overall survival (OS), safety, and neutrophil-to-lymphocyte ratio (NLR) biomarker. Results At a median follow-up time of 15.3 months (range: 3.1-71.3 months), the median PFS was 7.15 months (95% CI: 5.4-10.5) and the 6-month PFS was 54.0%. Median OS was 15.0 months (95% CI: 13.8-19.4) and 2-year OS rate was 17.1%. Patients receiving >3 cycles of adjuvant TMZ, undergoing surgery at progression, and presenting a post-concurrent NLR ≤6 experienced a significant improved OS with hazard ratios of 0.197 (P = .001), 0.46 (P = .049), and 0.38 (P = .021), respectively, on multivariable analysis. Age >65 years predicted for worse OS with hazard ratio of 3.92 (P = .037). Grade ≥3 thrombocytopenia occurred in 22.9%, grade ≥3 neutropenia in 20%, and grade ≥3 thromboembolic events in 14.3% of patients. There were no grade 5 events. Conclusion Our findings suggest a potential benefit of combining sunitinib with chemoradiation in newly diagnosed GBM patients with unmethylated MGMT status and provide a strong rationale to test this combination in future studies.
Collapse
Affiliation(s)
- Mame Daro Faye
- Division of Radiation Oncology, Mcgill University Health Centre
| | - Jacob Easaw
- Department of Oncology, Cross Cancer Institute
| | | | - Raman Agnihotram
- Department of Oncology, McGill University Health Centre Research Institute
| | | | - Frederic Lamonde
- Department of Oncology, McGill University Health Centre Research Institute
| | - Kevin Petrecca
- Division of Neurosurgery, McGill University Health Centre
| | - Scott Owen
- Department of Oncology, McGill University Health Centre Research Institute
| | | | - George Shenouda
- Division of Radiation Oncology, Mcgill University Health Centre
| | - Luis Souhami
- Division of Radiation Oncology, Mcgill University Health Centre
| | - Maryam Azam
- Centre for Translational Biology, The Research Institute of McGill University Health Centre, Montreal, Quebec, Canada
| | - Bushra Hossain
- Centre for Translational Biology, The Research Institute of McGill University Health Centre, Montreal, Quebec, Canada
| | - Jad Alkass
- Centre for Translational Biology, The Research Institute of McGill University Health Centre, Montreal, Quebec, Canada
| | - Siham Sabri
- Centre for Translational Biology, The Research Institute of McGill University Health Centre, Montreal, Quebec, Canada
| | - Bassam Abdulkarim
- Division of Radiation Oncology, Mcgill University Health Centre
- Centre for Translational Biology, The Research Institute of McGill University Health Centre, Montreal, Quebec, Canada
| |
Collapse
|
3
|
Faye MD, Sabri S, Robles PD, Easaw J, Agnihotram R, Torres-Vasquez A, Panet-Raymond V, Shenouda G, Souhami L, Abdulkarim B. 4: A Phase II Trial of Concurrent Sunitinib, Temozolomide and Radiation Therapy Followed by Adjuvant Temozolomide for Newly Diagnosed Glioblastoma Patients with an Unmethylated MGMT Gene Promoter (A01-M121-11A, MCG1132). Radiother Oncol 2022. [DOI: 10.1016/s0167-8140(22)04283-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/14/2022]
|
4
|
Naseri H, Skamene S, Tolba M, Faye MD, Ramia P, Khriguian J, Patrick H, Andrade Hernandez AX, David M, Kildea J. Radiomics-based machine learning models to distinguish between metastatic and healthy bone using lesion-center-based geometric regions of interest. Sci Rep 2022; 12:9866. [PMID: 35701461 PMCID: PMC9198102 DOI: 10.1038/s41598-022-13379-8] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/13/2022] [Accepted: 05/24/2022] [Indexed: 12/17/2022] Open
Abstract
Radiomics-based machine learning classifiers have shown potential for detecting bone metastases (BM) and for evaluating BM response to radiotherapy (RT). However, current radiomics models require large datasets of images with expert-segmented 3D regions of interest (ROIs). Full ROI segmentation is time consuming and oncologists often outline just RT treatment fields in clinical practice. This presents a challenge for real-world radiomics research. As such, a method that simplifies BM identification but does not compromise the power of radiomics is needed. The objective of this study was to investigate the feasibility of radiomics models for BM detection using lesion-center-based geometric ROIs. The planning-CT images of 170 patients with non-metastatic lung cancer and 189 patients with spinal BM were used. The point locations of 631 BM and 674 healthy bone (HB) regions were identified by experts. ROIs with various geometric shapes were centered and automatically delineated on the identified locations, and 107 radiomics features were extracted. Various feature selection methods and machine learning classifiers were evaluated. Our point-based radiomics pipeline was successful in differentiating BM from HB. Lesion-center-based segmentation approach greatly simplifies the process of preparing images for use in radiomics studies and avoids the bottleneck of full ROI segmentation.
Collapse
Affiliation(s)
- Hossein Naseri
- Medical Physics Unit, McGill University, Montreal, QC, Canada.
| | - Sonia Skamene
- Department of Radiation Oncology, McGill University Health Center (MUHC), Montreal, QC, Canada
| | - Marwan Tolba
- Department of Radiation Oncology, McGill University Health Center (MUHC), Montreal, QC, Canada
| | - Mame Daro Faye
- Department of Radiation Oncology, McGill University Health Center (MUHC), Montreal, QC, Canada
| | - Paul Ramia
- Department of Radiation Oncology, McGill University Health Center (MUHC), Montreal, QC, Canada
| | - Julia Khriguian
- Department of Radiation Oncology, McGill University Health Center (MUHC), Montreal, QC, Canada
| | - Haley Patrick
- Medical Physics Unit, McGill University, Montreal, QC, Canada
| | | | - Marc David
- Department of Radiation Oncology, McGill University Health Center (MUHC), Montreal, QC, Canada
| | - John Kildea
- Medical Physics Unit, McGill University, Montreal, QC, Canada
| |
Collapse
|
5
|
Giraud N, Benziane-Ouaritini N, Schick U, Beauval JB, Chaddad A, Niazi T, Faye MD, Supiot S, Sargos P, Latorzeff I. Post-Operative Radiotherapy in Prostate Cancer: Is It Time for a Belt and Braces Approach? Front Oncol 2021; 11:781040. [PMID: 34881187 PMCID: PMC8647553 DOI: 10.3389/fonc.2021.781040] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/22/2021] [Accepted: 10/27/2021] [Indexed: 11/23/2022] Open
Abstract
Approximately 30% of patients treated with radical prostatectomy (RP) for prostate cancers experience biochemical recurrence (BCR). Post-operative radiation therapy (RT) can be either offered immediately after the surgery in case of aggressive pathological features or proposed early if BCR occurs. Until recently, little data were available regarding the optimal RT timing, protocol, volumes to treat, and the benefit of adding androgen deprivation therapies to post-operative RT. In this review, we aim to pragmatically discuss current literature data on these points. Early salvage RT appears to be the optimal post-operative approach, improving oncological outcomes especially with low prostate-specific antigen (PSA) levels, as well as sparing several unnecessary adjuvant treatments. The standard RT dose is still 64–66 Gy to the prostate bed in conventional fractionation, but hypofractionation protocols are emerging pending on late toxicity data. Several scientific societies have published contouring atlases, even though they are heterogeneous and deserve future consensus. During salvage RT, the inclusion of pelvic lymph nodes is also controversial, but preliminary data show a possible benefit for PSA > 0.34 ng/ml at the cost of increased hematological side effects. Concomitant ADT and its duration are also discussed, possibly advantageous (at least in terms of metastasis-free survival) for PSA rates over 0.6 ng/ml, taking into account life expectancy and cardiovascular comorbidities. Intensified regimens, for instance, with new-generation hormone therapies, could further improve outcomes in carefully selected patients. Finally, recent advances in molecular imaging, as well as upcoming breakthroughs in genomics and artificial intelligence tools, could soon reshuffle the cards of the current therapeutic strategy.
Collapse
Affiliation(s)
- Nicolas Giraud
- Radiation Oncology Department, Institut Bergonié, Bordeaux, France
| | | | - Ulrike Schick
- Radiation Oncology Department, University Hospital, Brest, France
| | | | - Ahmad Chaddad
- School of Artificial Intelligence, Guilin University of Electronic Technology, Guilin, China
| | - Tamim Niazi
- Division of Radiation Oncology, Department of Oncology, McGill University, Montreal, QC, Canada
| | - Mame Daro Faye
- Division of Radiation Oncology, Department of Oncology, McGill University, Montreal, QC, Canada
| | - Stéphane Supiot
- Radiation Oncology Department, Institut de Cancérologie de l'Ouest, Nantes Saint-Herblain, France
| | - Paul Sargos
- Radiation Oncology Department, Institut Bergonié, Bordeaux, France
| | - Igor Latorzeff
- Radiation Oncology Department, Clinique Pasteur, Toulouse, France
| |
Collapse
|
6
|
Faye MD, Sabri S, De Robles P, Agnihotram R, Torres-Vasquez A, Easaw J, Abdulkarim B. SYST-08. A phase II trial of concurrent Sunitinib, Temozolomide and Radiation Therapy followed by adjuvant Temozolomide for newly diagnosed Glioblastoma patients with an unmethylated MGMT gene promoter (A01-M121-11A, McG1132). Neurooncol Adv 2021. [PMCID: PMC8453790 DOI: 10.1093/noajnl/vdab112.036] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Abstract
INTRODUCTION
Despite advances in treatment modalities, the overall prognosis of GBM remains dismal, particularly for patients with unmethylated MGMT promoter. Thus, alternative treatment strategies are warranted. Our group has previously shown that addition of Sunitinib (SU11248) to standard therapy significantly improved the response of unmethylated MGMT cells through decreased angiogenicity and tumorigenicity. In this phase II trial, we tested for the first time the combination of Sunitinib with RT and Temozolomide in newly diagnosed MGMT unmethylated GBM patients.
METHODS
Patients with histologically confirmed WHO Grade IV GBM and MS-PCR confirmed unmethylated MGMT promoter, age 18-70, KPS ≥70, life expectancy ≥6 months were eligible. 41 patients treated between 2012 and 2017 were screened, 37 of which were eligible. Patients received 12.5 mg of daily Sunitinib for 7 days, followed by concurrent RT, Temozolomide and 12.5 mg Sunitinib for 6 weeks, then adjuvant Temozolomide x6 cycles. RT and Temozolomide doses were as per standard of care. Primary objective was PFS as assessed by RANO criteria, secondary objectives were OS and safety.
RESULTS
Median follow-up time was 15 months. Median PFS was 7 months (95%CI, 6.7-7.2) and 6-month PFS was 59.3%. Median OS was 13 months (95%CI, 12.62-13.37) and 2-year OS was 17.8%. Two patients had OS >50 months, with one surviving 71 months. Having received >3 cycles of adjuvant Temozolomide, surgery at progression or age ≤65 significantly predicted for better OS, with hazard ratios of 0.184 (p=0.001), 0.402 (p=0.026) and 10.017 (for age >65, p=0.002) respectively. Grade ≥3 thrombocytopenia occurred in 18.9% of patients, grade ≥3 neutropenia in 10.8% and grade ≥3 thromboembolic events in 13.5%. There were no grade 5 evens.
CONCLUSION
Addition of Sunitinib to RT and Temozolomide was well tolerated and survival outcomes compared favorably to the current standard of care for GBM patients with unmethylated MGMT promoter status.
Collapse
Affiliation(s)
- Mame Daro Faye
- Department of Radiation Oncology, Cedars Cancer Centre, McGill University Health Centre, Montreal, QC, Canada
| | - Siham Sabri
- McGill University Heatlh Centre Research Institute, Montreal, QC, Canada
- Department of Pathology, Faculty of Medicine and Health Sciences, McGill University, Montreal, QC, Canada
| | - Paula De Robles
- Division of Neuro-Oncology, Tom Baker Cancer Center and University of Calgary, Calgary, Alberta, Canada
| | - Raman Agnihotram
- McGill University Heatlh Centre Research Institute, Montreal, QC, Canada
| | | | - Jacob Easaw
- Division of Medical Oncology, Tom Baker Cancer Center and University of Calgary, Calgary, Alberta, Canada
| | - Bassam Abdulkarim
- Department of Radiation Oncology, Cedars Cancer Centre, McGill University Health Centre, Montreal, QC, Canada
- Department of Medicine, Division of Experimental Medicine, McGill University, Montreal, QC, Canada
| |
Collapse
|
7
|
Sargos P, Baumann BC, Faye MD, Fonteyne V, Eccles CL. A Tailored Radiation Therapy Strategy for Older Patients With Localized Bladder Cancer Not Eligible for Curative Treatment. Int J Radiat Oncol Biol Phys 2021; 110:425-428. [PMID: 33989576 DOI: 10.1016/j.ijrobp.2021.01.009] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/30/2020] [Accepted: 01/07/2021] [Indexed: 10/21/2022]
Affiliation(s)
- Paul Sargos
- Department of Radiation Oncology, Institut Bergonié, Bordeaux, France.
| | - Brian C Baumann
- Department of Radiation Oncology, Washington University in St. Louis, St. Louis, Missouri
| | - Mame Daro Faye
- Department of Radiation Oncology, McGill University Health Centre, Montréal, Canada
| | - Véronique Fonteyne
- Department of Radiation Oncology, Ghent University Hospital, Ghent, Belgium
| | - Cynthia L Eccles
- The Christie NHS Foundation Trust and The University of Manchester, Manchester, United Kingdom
| |
Collapse
|
8
|
Sargos P, Faye MD, Bacci M, Supiot S, Latorzeff I, Azria D, Niazi TM, Vuong T, Vendrely V, de Crevoisier R. Late Gastrointestinal Tolerance After Prostate Radiotherapy: Is the Anal Canal the Culprit? A Narrative Critical Review. Front Oncol 2021; 11:666962. [PMID: 34221983 PMCID: PMC8242201 DOI: 10.3389/fonc.2021.666962] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/11/2021] [Accepted: 05/13/2021] [Indexed: 11/30/2022] Open
Abstract
Introduction Late gastro-intestinal toxicities (LGIT) secondary to pelvic radiotherapy (RT) are well described in the literature. LGIT are mainly related to rectal or ano-rectal irradiation; however, involvement of the anal canal (AC) in the occurrence of LGIT remains poorly described and understood. Materials and Methods The aim of this work was to explore the potential role of the AC in the development of LGIT after prostate irradiation and identify predictive factors that could be optimized in order to limit these toxicities. This narrative literature review was realized using the Pubmed database. We identified original articles published between June 1997 and July 2019, relating to LGIT after RT for localized prostate cancer and for which AC was identified independently. Articles defining the AC as part of an anorectal or rectal volume only were excluded. Results A history of abdominal surgery or cardio-vascular risk, anticoagulant or tobacco use, and the occurrence of acute GIT during RT increases the risk of LGIT. A dose-effect relationship was identified between dose to the AC and development of LGIT. Identification and contouring of the AC and adjacent anatomical structures (muscles or nerves) are justified to apply specific dose constraints. As a limitation, our review mainly considered on 3DCRT which is no longer the standard of care nowadays; we did not identify any reports in the literature using moderately hypofractionated RT for the prostate and AC specific dosimetry. Conclusion These results suggest that the AC may have an important role in the development of LGIT after pelvic RT for prostate cancer. The individualization of the AC during planning should be recommended in prospective studies.
Collapse
Affiliation(s)
- Paul Sargos
- Department of Radiation Oncology, Institut Bergonié, Bordeaux Cedex, France
| | - Mame Daro Faye
- Department of Radiation Oncology, Jewish General Hospital, Montreal, QC, Canada
| | - Manon Bacci
- Department of Radiation Oncology, Institut Bergonié, Bordeaux Cedex, France
| | - Stéphane Supiot
- Department of Radiation Oncology, Institut de Cancérologie de l'Ouest, Saint-Herblain, France
| | - Igor Latorzeff
- Department of Radiation Oncology, Clinique Pasteur, Toulouse, France
| | - David Azria
- Department of Radiation Oncology, Institut de Cancérologie de Montpellier, Montpellier, France
| | - Tamim M Niazi
- Department of Radiation Oncology, Jewish General Hospital, Montreal, QC, Canada
| | - Te Vuong
- Department of Radiation Oncology, Jewish General Hospital, Montreal, QC, Canada
| | - Véronique Vendrely
- Department of Radiation Oncology, Bordeaux University Hospital, Bordeaux, France
| | | |
Collapse
|
9
|
|
10
|
Faye MD, Araujo MP, Alrabiah K, Wissing MD, Alfieri J. 102: 2D Icru-Based Versus 3D Image-Guided Planning in High Dose Rate Brachytherapy for Cervical Cancer - A Study on Efficacy and Treatment-Related Toxicities. Radiother Oncol 2020. [DOI: 10.1016/s0167-8140(20)30994-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
|
11
|
Diongue K, Kébé O, Faye MD, Samb D, Diallo MA, Ndiaye M, Seck MC, Badiane AS, Ranque S, Ndiaye D. MALDI-TOF MS identification of Malassezia species isolated from patients with pityriasis versicolor at the seafarers' medical service in Dakar, Senegal. J Mycol Med 2018; 28:590-593. [PMID: 30340859 DOI: 10.1016/j.mycmed.2018.09.007] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/05/2018] [Revised: 09/04/2018] [Accepted: 09/28/2018] [Indexed: 11/19/2022]
Abstract
Pityriasis versicolor (PV) is a superficial mycosis caused by yeast of the genus Malassezia. The most common isolated Malassezia species in PV lesions differ among M. furfur, M. globosa and M. sympodialis. We purpose to determine the distribution of Malassezia species in PV patients at the seafarers' medical service in Dakar, Senegal and to examine whether any association between identified Malassezia species and patients' profile. From May 2017 to August 2017, first a questionnaire was filled to get informative data before collection of skin scrapings taken from most scaly site using sterile scalpel blade and application of scotch® for direct examination (DE). At the laboratory, DE, culture and identification by MALDI-TOF MS were done. One hundred patients with PV - all men - were included with a mean age of 34 years. Among seafarers, 81% were sailors. Clinical prevalence of PV was highest in aged adults patients with ages of 31 to 60 years (56%). Seafarers with high level of education were less representative with only 2%. The mean duration of the PV was 26.83 months. 20% of subjects suffered lesions in more than one location. The chest was the most affected anatomical site. Furthermore, possible predisposing factors associated with PV were also detected. DE was positive in 95% but culture growth only in 46%. MALDI-TOF MS analysis of the positive cultures could be performed in 84.8% (39/46). Only M. furfur was identified in 100% (39/39). In definitive, M. furfur is the only causative agent of PV in Dakar.
Collapse
Affiliation(s)
- K Diongue
- Laboratoire de Parasitologie-Mycologie, CHU Aristide Le Dantec, BP 5005, Dakar, Senegal; Service de Parasitologie-Mycologie, Faculté de Médecine, de Pharmacie et d'Odontologie, Université Cheikh Anta Diop, BP 16477, Dakar, Senegal.
| | - O Kébé
- Laboratoire de Parasitologie-Mycologie, CHU Aristide Le Dantec, BP 5005, Dakar, Senegal
| | - M D Faye
- Service Médical des gens de Mer, Rue Vincent x Faidherbe, Dakar, Senegal
| | - D Samb
- Laboratoire de Parasitologie-Mycologie, CHU Aristide Le Dantec, BP 5005, Dakar, Senegal
| | - M A Diallo
- Laboratoire de Parasitologie-Mycologie, CHU Aristide Le Dantec, BP 5005, Dakar, Senegal
| | - M Ndiaye
- Laboratoire de Parasitologie-Mycologie, CHU Aristide Le Dantec, BP 5005, Dakar, Senegal; Service de Parasitologie-Mycologie, Faculté de Médecine, de Pharmacie et d'Odontologie, Université Cheikh Anta Diop, BP 16477, Dakar, Senegal
| | - M C Seck
- Laboratoire de Parasitologie-Mycologie, CHU Aristide Le Dantec, BP 5005, Dakar, Senegal; Service de Parasitologie-Mycologie, Faculté de Médecine, de Pharmacie et d'Odontologie, Université Cheikh Anta Diop, BP 16477, Dakar, Senegal
| | - A S Badiane
- Laboratoire de Parasitologie-Mycologie, CHU Aristide Le Dantec, BP 5005, Dakar, Senegal; Service de Parasitologie-Mycologie, Faculté de Médecine, de Pharmacie et d'Odontologie, Université Cheikh Anta Diop, BP 16477, Dakar, Senegal
| | - S Ranque
- Institut hospitalo-universitaire Méditerranée infection, 13005 Marseille, France
| | - D Ndiaye
- Laboratoire de Parasitologie-Mycologie, CHU Aristide Le Dantec, BP 5005, Dakar, Senegal; Service de Parasitologie-Mycologie, Faculté de Médecine, de Pharmacie et d'Odontologie, Université Cheikh Anta Diop, BP 16477, Dakar, Senegal
| |
Collapse
|
12
|
Benzina S, Beauregard AP, Guerrette R, Jean S, Faye MD, Laflamme M, Maïcas E, Crapoulet N, Ouellette RJ, Robichaud GA. Pax-5 is a potent regulator of E-cadherin and breast cancer malignant processes. Oncotarget 2017; 8:12052-12066. [PMID: 28076843 PMCID: PMC5355325 DOI: 10.18632/oncotarget.14511] [Citation(s) in RCA: 19] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/13/2016] [Accepted: 12/16/2016] [Indexed: 01/06/2023] Open
Abstract
Pax-5, an essential transcription factor for B lymphocyte development, has been linked with the development and progression of lymphoid cancers and carcinoma. In contrast to B-cell cancer lesions, the specific expression signatures and roles of Pax-5 in breast cancer progression are relatively unknown. In the present study, we set out to profile Pax-5 expression in mammary tissues and elucidate the cellular and molecular roles of Pax-5 in breast cancer processes. Using immunohistology on mammary tissue arrays, Pax-5 was detected in a total of 298/306 (97.6%) samples tested. Interestingly, our studies reveal that Pax-5 inhibits aggressive features and confers anti-proliferative effects in breast carcinoma cells in contrast to its oncogenic properties in B cell cancers. More precisely, Pax-5 suppressed breast cancer cell migration, invasion and tumor spheroid formation while concomitantly promoting cell adhesion properties. We also observed that Pax-5 inhibited and reversed breast cancer epithelial to mesenchymal phenotypic transitioning. Mechanistically, we found that the Pax-5 transcription factor binds and induces gene expression of E-cadherin, a pivotal regulator of epithelialisation. Globally, we demonstrate that Pax-5 is predominant expressed factor in mammary epithelial cells. We also present an important role for Pax-5 in the phenotypic transitioning processes and aggressive features associated with breast cancer malignancy and disease progression.
Collapse
Affiliation(s)
- Sami Benzina
- Université de Moncton, Département de chimie et biochimie, Moncton, NB, E1A 3E9, Canada
- Atlantic Cancer Research Institute, Moncton, NB, E1C 8×3, Canada
| | - Annie-Pier Beauregard
- Université de Moncton, Département de chimie et biochimie, Moncton, NB, E1A 3E9, Canada
- Atlantic Cancer Research Institute, Moncton, NB, E1C 8×3, Canada
| | - Roxann Guerrette
- Université de Moncton, Département de chimie et biochimie, Moncton, NB, E1A 3E9, Canada
- Atlantic Cancer Research Institute, Moncton, NB, E1C 8×3, Canada
| | - Stéphanie Jean
- Université de Moncton, Département de chimie et biochimie, Moncton, NB, E1A 3E9, Canada
- Atlantic Cancer Research Institute, Moncton, NB, E1C 8×3, Canada
| | - Mame Daro Faye
- Université de Moncton, Département de chimie et biochimie, Moncton, NB, E1A 3E9, Canada
- Atlantic Cancer Research Institute, Moncton, NB, E1C 8×3, Canada
| | - Mark Laflamme
- Université de Moncton, Département de chimie et biochimie, Moncton, NB, E1A 3E9, Canada
- Department of Fisheries and Oceans Canada, Molecular Biology Unit, Moncton, NB, E1C 9B6, Canada
| | - Emmanuel Maïcas
- Université de Moncton, Département de chimie et biochimie, Moncton, NB, E1A 3E9, Canada
- Atlantic Cancer Research Institute, Moncton, NB, E1C 8×3, Canada
- Georges-L.-Dumont University Hospital Centre, Pathology Department, Moncton, NB, E1C 2Z3, Canada
| | | | - Rodney J. Ouellette
- Université de Moncton, Département de chimie et biochimie, Moncton, NB, E1A 3E9, Canada
- Atlantic Cancer Research Institute, Moncton, NB, E1C 8×3, Canada
| | - Gilles A. Robichaud
- Université de Moncton, Département de chimie et biochimie, Moncton, NB, E1A 3E9, Canada
- Atlantic Cancer Research Institute, Moncton, NB, E1C 8×3, Canada
| |
Collapse
|
13
|
Thakor N, Smith MD, Roberts L, Faye MD, Patel H, Wieden HJ, Cate JHD, Holcik M. Cellular mRNA recruits the ribosome via eIF3-PABP bridge to initiate internal translation. RNA Biol 2016; 14:553-567. [PMID: 26828225 PMCID: PMC5449081 DOI: 10.1080/15476286.2015.1137419] [Citation(s) in RCA: 23] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/04/2023] Open
Abstract
IRES-mediated translation of key cell fate regulating genes has been implicated in tumorigenesis. Concerted action of canonical eukaryotic initiation factors and IRES transacting factors (ITAFs) was shown to regulate cellular IRES mediated translation; however, the precise molecular mechanism of ribosome recruitment to cellular IRESes remains unclear. Here we show that the X-linked inhibitor of apoptosis (XIAP) IRES operates in an evolutionary conserved viral like mode and the structural integrity, particularly in the vicinity of AUG, is critical for ribosome recruitment. The binding of eIF3 together with PABP potentiates ribosome recruitment to the IRES. Our data support the model in which eIF3 binds directly to the XIAP IRES RNA in a structure-dependent manner and acts as a scaffold for IRES RNA, PABP and the 40S ribosome.
Collapse
Affiliation(s)
- Nehal Thakor
- a Apoptosis Research Center , Children's Hospital of Eastern Ontario Research Institute , Ottawa , Ontario , Canada.,c Department of Chemistry and Biochemistry , Alberta RNA Research and Training Institute, University of Lethbridge , Lethbridge , AB , Canada
| | - M Duane Smith
- d Department of Molecular and Cell Biology , University of California , Berkeley , CA , USA
| | - Luc Roberts
- c Department of Chemistry and Biochemistry , Alberta RNA Research and Training Institute, University of Lethbridge , Lethbridge , AB , Canada
| | - Mame Daro Faye
- a Apoptosis Research Center , Children's Hospital of Eastern Ontario Research Institute , Ottawa , Ontario , Canada
| | - Harshil Patel
- c Department of Chemistry and Biochemistry , Alberta RNA Research and Training Institute, University of Lethbridge , Lethbridge , AB , Canada
| | - Hans-Joachim Wieden
- c Department of Chemistry and Biochemistry , Alberta RNA Research and Training Institute, University of Lethbridge , Lethbridge , AB , Canada
| | - Jamie H D Cate
- d Department of Molecular and Cell Biology , University of California , Berkeley , CA , USA
| | - Martin Holcik
- a Apoptosis Research Center , Children's Hospital of Eastern Ontario Research Institute , Ottawa , Ontario , Canada.,b Department of Pediatrics , University of Ottawa , Ottawa , Ontario , Canada
| |
Collapse
|
14
|
Abstract
Regulation of protein synthesis represents a key control point in cellular response to stress. In particular, discreet RNA regulatory elements were shown to allow to selective translation of specific mRNAs, which typically encode for proteins required for a particular stress response. Identification of these mRNAs, as well as the characterization of regulatory mechanisms responsible for selective translation has been at the forefront of molecular biology for some time. Polysome profiling is a cornerstone method in these studies. The goal of polysome profiling is to capture mRNA translation by immobilizing actively translating ribosomes on different transcripts and separate the resulting polyribosomes by ultracentrifugation on a sucrose gradient, thus allowing for a distinction between highly translated transcripts and poorly translated ones. These can then be further characterized by traditional biochemical and molecular biology methods. Importantly, combining polysome profiling with high throughput genomic approaches allows for a large scale analysis of translational regulation.
Collapse
Affiliation(s)
- Mame Daro Faye
- Apoptosis Research Centre, Children's Hospital of Eastern Ontario Research Institute and Department of Biochemistry, Microbiology and Immunology, University of Ottawa
| | | | - Martin Holcik
- Apoptosis Research Centre, Children's Hospital of Eastern Ontario Research Institute and Department of Pediatrics, University of Ottawa;
| |
Collapse
|
15
|
Faye MD, Graber TE, Beug S, Xiang X, Wild B, Langlois S, Cowan KN, Korneluk RG, Holcik M. Abstract 4256: Characterization of the cellular inhibitor of apoptosis 1 (cIAP1) IRES trans-acting factors and their contribution to apoptotic resistance in rhabdomyosarcomas. Cancer Res 2014. [DOI: 10.1158/1538-7445.am2014-4256] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
The cellular inhibitor of apoptosis protein 1 (cIAP1) is a key regulator of the NFκB signaling pathway and of caspase-8 mediated cell death in mammalian cells. cIAP1 expression is regulated at the translation level via an internal ribosome entry site (IRES). We have previously identified and characterized two IRES trans-acting factors - NF45 and IGF2BP1 - that bind specifically to the cIAP1 IRES and regulates its activity in the context of cell division and apoptosis.
In this study, we characterized the minimal requirement of the cIAP1 IRES for these IRES trans-acting factors as well as other canonical translation factors. We also studied the contribution of cIAP1 expression regulation by these IRES trans-acting factors on the apoptotic resistance of rhabdomyosarcoma cancer cells. In particular, we show that the IRES trans-acting factor IGF2BP1 is overexpressed in a panel of rhabdomyosarcoma primary tumors and cell lines where it drives cIAP1 IRES-mediated translation, contributing to increased resistance to cell death. We also show that targeting cIAP1 by either IGF2BP1 knock-down or IAP antagonists delay RMS tumour growth in the presence of TNFα and improve survival in mice.
Citation Format: Mame Daro Faye, Tyson E. Graber, Shawn Beug, Xiao Xiang, Benjamin Wild, Stephanie Langlois, Kyle N. Cowan, Robert G. Korneluk, Martin Holcik. Characterization of the cellular inhibitor of apoptosis 1 (cIAP1) IRES trans-acting factors and their contribution to apoptotic resistance in rhabdomyosarcomas. [abstract]. In: Proceedings of the 105th Annual Meeting of the American Association for Cancer Research; 2014 Apr 5-9; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2014;74(19 Suppl):Abstract nr 4256. doi:10.1158/1538-7445.AM2014-4256
Collapse
Affiliation(s)
| | | | - Shawn Beug
- 1Apotosis Research Centre, Ottawa, Ontario, Canada
| | - Xiao Xiang
- 1Apotosis Research Centre, Ottawa, Ontario, Canada
| | | | | | | | | | | |
Collapse
|
16
|
Faye MD, Holcik M. The role of IRES trans-acting factors in carcinogenesis. Biochim Biophys Acta 2014; 1849:887-97. [PMID: 25257759 DOI: 10.1016/j.bbagrm.2014.09.012] [Citation(s) in RCA: 37] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Received: 08/01/2014] [Revised: 09/09/2014] [Accepted: 09/14/2014] [Indexed: 02/06/2023]
Abstract
Regulation of protein expression through RNA metabolism is a key aspect of cellular homeostasis. Upon specific cellular stresses, distinct transcripts are selectively controlled to modify protein output in order to quickly and appropriately respond to stress. Reprogramming of the translation machinery is one node of this strict control that typically consists of an attenuation of the global, cap-dependent translation and accompanying switch to alternative mechanisms of translation initiation, such as internal ribosome entry site (IRES)-mediated initiation. In cancer, many aspects of the RNA metabolism are frequently misregulated to provide cancer cells with a growth and survival advantage. This includes changes in the expression and function of RNA binding proteins termed IRES trans-acting factors (ITAFs) that are central to IRES translation. In this review, we will examine select emerging, as well as established, ITAFs with important roles in cancer initiation and progression, and in particular their role in IRES-mediated translation. This article is part of a Special Issue entitled: Translation and Cancer.
Collapse
Affiliation(s)
- Mame Daro Faye
- Apoptosis Research Centre, Children's Hospital of Eastern Ontario Research Institute, 401 Smyth Road, Ottawa K1H 8L1, Canada; Department of Biochemistry, Microbiology and Immunology, University of Ottawa, 451 Smyth Road, Ottawa K1H 8M5, Canada
| | - Martin Holcik
- Apoptosis Research Centre, Children's Hospital of Eastern Ontario Research Institute, 401 Smyth Road, Ottawa K1H 8L1, Canada; Department of Biochemistry, Microbiology and Immunology, University of Ottawa, 451 Smyth Road, Ottawa K1H 8M5, Canada; Department of Pediatrics, University of Ottawa, 451 Smyth Road, Ottawa K1H 8M5, Canada.
| |
Collapse
|
17
|
Faye A, Faye MD, Leye MM, Diongue M, Niang K, Camara MD, Tal-Dia A. [Study of determinants of unprotected sex in sailors of the Senegalese merchant navy]. ACTA ACUST UNITED AC 2014; 107:115-20. [PMID: 24639134 DOI: 10.1007/s13149-014-0353-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/21/2013] [Accepted: 02/11/2014] [Indexed: 10/25/2022]
Abstract
Sailors are a mobile population travelling a lot and therefore being often exposed to casual sex. The aim of this study is to analyze the determinants of unprotected sex among sailors in Senegal. A descriptive and analytical study was conducted among sailors of the merchant navy. Data on knowledge, attitudes and practices were collected during a personal interview. A multivariate analysis was performed using a multiple logistic regression. A total of 400 sailors were interviewed, 57.9% had casual sex of whom 23.7% were not protected. Sexual intercourse without protection was more common among the uneducated (OR = 2.29 [1.23 to 5.99]) and married (OR = 2.29 [1.23-5.99]). Sailors who thought that using condom reduces pleasure during sexual intercourse (OR = 2.5 [1.2-5.1]) and those who consumed alcohol (OR = 5.4 [2.07-14.2]) were less protected during casual sex. Sexual contact is one of the main modes of transmission of HIV / AIDS. Sailors often have unprotected sex. Interventions using specific ways must be performed taking into account the mobility of these men who are often uneducated.
Collapse
Affiliation(s)
- A Faye
- Institut de santé et développement, UCAD, Dakar, Sénégal,
| | | | | | | | | | | | | |
Collapse
|
18
|
Faye MD, Graber T, Langlois S, Cowan K, Holcik M. Abstract 827: Identification of the insulin-like growth factor 2 mRNA binding protein (IGF2BP1) as an important regulator of cIAP1 translation and apoptosis in rhabdomyosarcomas. Cancer Res 2013. [DOI: 10.1158/1538-7445.am2013-827] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Rhabdomyosarcoma, a neoplasm characterized by undifferentiated myoblats-like cells, is the most common soft tissue sarcoma of childhood and represents 3-4% of all childhood cancers. IGF2BP1 is an oncofetal protein that was first identified in the rhabdomyosarcoma RD cell line and was shown to be overexpressed in a variety of cancers. Our group has previously identified IGF2BP1 as a potential translation modulator of the cellular inhibitor of apoptosis protein 1 (cIAP1), a key regulator of the NFκB signaling pathway and of caspase-8 mediated cell death in mammalian cells. In this study, we report that IGF2BP1 and cIAP1 expression is upregulated in a panel of rhabdomyosarcoma cell lines. We also show that IGF2BP1 is a positive regulator of cIAP1 translation, specifically through an internal ribosome entry site (IRES) mechanism. Finally, we report that altering the levels of cIAP1 in two rhabdomyosarcoma cell lines, RH36 and RH41, either by IGF2BP1 knock-down or by a Smac mimetic coumpound, sensitizes these cells to TNFα-mediated cell death. Our results identify IGF2BP1 and cIAP1 as important regulators of apoptosis in rhabdomyosarcomas.
Citation Format: Mame Daro Faye, Tyson Graber, Stephanie Langlois, Kyle Cowan, Martin Holcik. Identification of the insulin-like growth factor 2 mRNA binding protein (IGF2BP1) as an important regulator of cIAP1 translation and apoptosis in rhabdomyosarcomas. [abstract]. In: Proceedings of the 104th Annual Meeting of the American Association for Cancer Research; 2013 Apr 6-10; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2013;73(8 Suppl):Abstract nr 827. doi:10.1158/1538-7445.AM2013-827
Collapse
Affiliation(s)
- Mame Daro Faye
- 1Apotosis Research Center, Children Hospital of Eastern Ontario Research Institute, Ottawa, Ontario, Canada
| | - Tyson Graber
- 2Montreal Neurogical Institute, Montreal, Quebec, Canada
| | - Stephanie Langlois
- 3Children Hospital of Eastern Ontario Research Institute, Ottawa, Ontario, Canada
| | - Kyle Cowan
- 3Children Hospital of Eastern Ontario Research Institute, Ottawa, Ontario, Canada
| | - Martin Holcik
- 1Apotosis Research Center, Children Hospital of Eastern Ontario Research Institute, Ottawa, Ontario, Canada
| |
Collapse
|
19
|
Liwak U, Faye MD, Holcik M. Translation control in apoptosis. Exp Oncol 2012; 34:218-230. [PMID: 23070007] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 06/01/2023]
Abstract
Regulation of protein synthesis, although known for many decades, has only recently begun to be recognized as a critical control mechanism for the maintenance of cellular homeostasis and cellular stress response. One of the key advantages of translational control is the ability of cells to rapidly reprogram the protein output in response to internal or external triggers. This is particularly important during cellular response to stress that may lead to apoptosis by providing cells with a fine tuning mechanism that tips the balance between cell survival or apoptosis. In the following review we highlight several distinct mechanisms of translation control and provide specific examples of translational control during apoptosis. This article is part of a Special Issue entitled "Apoptosis: Four Decades Later".
Collapse
Affiliation(s)
- U Liwak
- Apoptosis Research Centre, Children's Hospital of Eastern Ontario Research Institute, Ottawa, Canada
| | | | | |
Collapse
|
20
|
Faye MD, Ouellette R. Study of the activity of Estrogen Response Elements present on Pax‐5 promoter and their potential role on regulating Pax‐5 expression in breast cancer. FASEB J 2009. [DOI: 10.1096/fasebj.23.1_supplement.lb278] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
Affiliation(s)
- Mame Daro Faye
- Atlantic Cancer Research InstituteMonctonNBCanada
- Université de MonctonMonctonNBCanada
| | | |
Collapse
|